MedTrace Logo

Diagnostic and Translational Values of Point-of-care Blood Eosinophils and Exhaled Nitric Oxide (FeNO) in People Referred by Primary Care for Suspected Asthma

NCT05992519 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 123

Last updated 2025-11-19

No results posted yet for this study

Summary

Asthma is characterised by episodic symptoms (attacks) caused by airway inflammation and decreased airflow to the lungs. It affects 10% of the Canadian population and is the most common chronic disease in childhood. Despite its burden and its potential to be life-threatening, establishing the diagnosis takes time due to difficulty in accessing specialised breathing tests. Indeed, the current diagnostic strategy relies on a breathing test (spirometry) and, if non-diagnostic, a subsequent more complicated breathing test conducted in hospitals (a bronchial provocation test). Our dependence on the latter test must be confronted to the bottleneck created by our reliance on it and the difficulty to do these tests in children. Furthermore, within the current framework, people receiving a diagnosis do not know if they have active airway inflammation - a key feature with predicts increased susceptibility to asthma attacks and treatment responsiveness.

Our study's goal is to validate clinically accessible and useful diagnostic tests for peoplesuspected to have asthma. Specifically, we are interested in alternative tests that are a) achievable outside the hospital; b) useful markers of airway inflammation/risk c) can identify people at with a higher likelihood of responding to anti-inflammatory therapy. The two tests we are mainly interested in are:

* Exhaled nitric oxide (measured with a portable handheld machine)
* The blood eosinophil count (obtained on a general blood test) +/- Other tests which we might be able to develop within this cohort (e.g. urine tests)

Conditions

Interventions

DIAGNOSTIC_TEST

¸FeNO

FeNO measured with a NIOX VERO device after the methacholine challenge

Sponsors & Collaborators

  • Association Pulmonaire du Quebec

    collaborator OTHER

  • Réseau de Recherche en Santé Respiratoire du Québec

    collaborator UNKNOWN

  • AstraZeneca

    collaborator INDUSTRY

  • Fonds de la Recherche en Santé du Québec

    collaborator OTHER_GOV

  • Fondation JA DeSève

    collaborator UNKNOWN

  • Université de Sherbrooke

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-07
Primary Completion
2025-10-30
Completion
2025-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05992519 on ClinicalTrials.gov